EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension - 20/01/14
, Marion Delcroix, MD b, Emmanuel Bergot, MD c, Anco B. Boonstra, MD d, John Granton, MD e, David Langleben, MD f, Pilar Escribano Subías, MD g, Nazzareno Galiè, MD h, Thomas Pfister, PhD i, Jean-Christophe Lemarié, MSc j, Gérald Simonneau, MD aRésumé |
Background |
Continuous infusion of epoprostenol is the treatment of choice in patients with pulmonary arterial hypertension in functional classes III to IV. However, this treatment's limitations include instability at room temperature. A new epoprostenol formulation offers improved storage conditions and patient convenience.
Methods |
The EPITOME-2 trial was an open-label, prospective, multicenter, single-arm, phase IIIb study. Patients with pulmonary arterial hypertension on long-term, stable epoprostenol therapy were transitioned from epoprostenol with glycine and mannitol excipients (Flolan; GlaxoSmithKline, Durham, NC) to epoprostenol with arginine and sucrose excipients (Veletri; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland). Patients were followed up for 3 months, and dose adjustments were recorded. Efficacy measures included the 6-minute walk distance, hemodynamics assessed by right heart catheterization, and New York Heart Association functional class. Safety and tolerability of the transition were also evaluated. Quality of life was assessed using the Treatment Satisfaction Questionnaire for Medication.
Results |
Forty-two patients enrolled in the study, and 1 patient withdrew consent before treatment; thus, 41 patients received treatment and completed the study. Six patients required dose adjustments. There were no clinically relevant changes from baseline to month 3 in any of the efficacy end points. Adverse events were those previously described with intravenous prostacyclin therapy. Treatment Satisfaction Questionnaire for Medication scores showed an improvement from baseline to month 3 in the domain of treatment convenience.
Conclusions |
Transition from epoprostenol with glycine and mannitol excipients to epoprostenol with arginine and sucrose excipients did not affect treatment efficacy, raised no new safety or tolerability concerns, and provided patients with an increased sense of treatment convenience.
Le texte complet de cet article est disponible en PDF.Plan
| ☆ | This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| Randomized controlled trial registration no. NCT01431716. |
Vol 167 - N° 2
P. 210-217 - février 2014 Retour au numéro
Article précédent
- Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: A multinational 10-year experience : Data from the Multicenter International CRT Study
- Maurizio Gasparini, Christophe Leclercq, Cheuk-Man Yu, Angelo Auricchio, Jonathan S. Steinberg, Barbara Lamp, Catherine Klersy, Francisco Leyva
- Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study
- Kelly M. Chin, David B. Badesch, Ivan M. Robbins, Victor F. Tapson, Harold I. Palevsky, Nick H. Kim, Steven M. Kawut, Adaani Frost, Wade W. Benton, Jean-Christophe Lemarie, Frederic Bodin, Lewis J. Rubin, Vallerie McLaughlin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?